Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8677MR)

This product GTTS-WQ8677MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8677MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5837MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ1818MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ13898MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ15138MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ5670MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ10528MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ12672MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ4515MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW